Question · Q4 2025
Ghansham Panjabi asked if the Q4 emergency medicine performance aligned with internal projections, whether Q1 EPS guidance could proxy Q2, and about the funding strategy for the new $600 million share repurchase authorization.
Answer
CFO Vanessa Kanu confirmed that Q4 emergency medicine performance was in line with expectations. She declined to provide specific Q2 guidance but reiterated the $65 million full-year emergency medicine headwind, mostly in H1, and that full-year models should capture this. President and CEO Stephan Tanda expressed confidence in the company's momentum despite the headwinds. CFO Vanessa Kanu stated the $600 million authorization offers flexibility and can be funded by both excess free cash flow and flexing the balance sheet.
Ask follow-up questions
Fintool can predict
ATR's earnings beat/miss a week before the call